Medicis kept at outperform by RBC

RBC Capital Markets analyst Ken Trbovich maintained Medicis Pharmaceutical Corp. at outperform, above average risk, and a $34 price target. IMS data shows 6,708 Solodyn prescriptions for the week ended Sept. 1, up 5.4% from the prior week. The analyst said oral acne prescriptions continue on pace above RBC estimates. Together with the old Dynacin brand, Medicis' acne franchise is up 82% from the comparable week last year. Combined prescriptions (8,941) continue on pace to exceed the 32,000 prescriptions modeled for August. Shares of the Scottsdale, Ariz.-based specialty pharmaceutical company were up 55 cents, or 1.85%, at $30.26. (NYSE: MRX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.